Cargando…

International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility

Background: The demand for implementing a new listing scheme to expedite patient access to novel oncology drugs has increased in South Korea. This study was conducted to compare the prices of anticancer drugs between eight countries and to explore the feasibility of a ‘pre-listing and post-evaluatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jae Ho, Kim, Dae Jung, Suh, Kangho, You, Jaeeun, Lee, Je Ho, Joung, Kyung In, Suh, Dong Churl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830510/
https://www.ncbi.nlm.nih.gov/pubmed/33466893
http://dx.doi.org/10.3390/ijerph18020670
_version_ 1783641431857954816
author Jung, Jae Ho
Kim, Dae Jung
Suh, Kangho
You, Jaeeun
Lee, Je Ho
Joung, Kyung In
Suh, Dong Churl
author_facet Jung, Jae Ho
Kim, Dae Jung
Suh, Kangho
You, Jaeeun
Lee, Je Ho
Joung, Kyung In
Suh, Dong Churl
author_sort Jung, Jae Ho
collection PubMed
description Background: The demand for implementing a new listing scheme to expedite patient access to novel oncology drugs has increased in South Korea. This study was conducted to compare the prices of anticancer drugs between eight countries and to explore the feasibility of a ‘pre-listing and post-evaluation’ scheme to expedite patient access to oncology drugs. Methods: This study included 34 anticancer drugs, which were reimbursed between 1 January 2007 and 31 December 2017. The unit price and sales volume of the study drugs were collected from eight countries and IQVIA data, respectively. The prices were adjusted to estimate the ex-factory prices using the discount/rebate rate suggested by the Health Insurance Review Agency (HIRA). The four price indices of Laspeyres, Paasche, Fisher, and the unweighted index were calculated using the price in each country, the average price, and lowest price among the study countries. Each currency was converted using the currency exchange rate and purchasing power parity (PPP). The budget impact of implementing the proposed pre-listing and post-evaluation scheme on payers was calculated. Results: Based on the currency exchange rate, anticancer drug prices were higher in other countries (index range: 1.05–2.78) compared to Korea. The prices in Korea were similar to countries with the lowest prices. When the PPP was applied, prices were higher in the US, Germany, Italy, and Japan than in Korea (range: 1.10–2.13); however, the prices were lower in the UK, France, and Switzerland than in Korea (range: 0.72–0.99). The financial burden of implementing the pre-listing and post-evaluation scheme was calculated at 0.83% of the total anticancer drug sales value in Korea from 2013–2017. Conclusions: The prices of anticancer drugs in Korea were similar to the lowest prices among the seven other study countries. A pre-listing and post-evaluation scheme should be considered to improve patient access to novel anticancer drugs by reducing the reimbursement review time and uncertainties.
format Online
Article
Text
id pubmed-7830510
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78305102021-01-26 International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility Jung, Jae Ho Kim, Dae Jung Suh, Kangho You, Jaeeun Lee, Je Ho Joung, Kyung In Suh, Dong Churl Int J Environ Res Public Health Article Background: The demand for implementing a new listing scheme to expedite patient access to novel oncology drugs has increased in South Korea. This study was conducted to compare the prices of anticancer drugs between eight countries and to explore the feasibility of a ‘pre-listing and post-evaluation’ scheme to expedite patient access to oncology drugs. Methods: This study included 34 anticancer drugs, which were reimbursed between 1 January 2007 and 31 December 2017. The unit price and sales volume of the study drugs were collected from eight countries and IQVIA data, respectively. The prices were adjusted to estimate the ex-factory prices using the discount/rebate rate suggested by the Health Insurance Review Agency (HIRA). The four price indices of Laspeyres, Paasche, Fisher, and the unweighted index were calculated using the price in each country, the average price, and lowest price among the study countries. Each currency was converted using the currency exchange rate and purchasing power parity (PPP). The budget impact of implementing the proposed pre-listing and post-evaluation scheme on payers was calculated. Results: Based on the currency exchange rate, anticancer drug prices were higher in other countries (index range: 1.05–2.78) compared to Korea. The prices in Korea were similar to countries with the lowest prices. When the PPP was applied, prices were higher in the US, Germany, Italy, and Japan than in Korea (range: 1.10–2.13); however, the prices were lower in the UK, France, and Switzerland than in Korea (range: 0.72–0.99). The financial burden of implementing the pre-listing and post-evaluation scheme was calculated at 0.83% of the total anticancer drug sales value in Korea from 2013–2017. Conclusions: The prices of anticancer drugs in Korea were similar to the lowest prices among the seven other study countries. A pre-listing and post-evaluation scheme should be considered to improve patient access to novel anticancer drugs by reducing the reimbursement review time and uncertainties. MDPI 2021-01-14 2021-01 /pmc/articles/PMC7830510/ /pubmed/33466893 http://dx.doi.org/10.3390/ijerph18020670 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jung, Jae Ho
Kim, Dae Jung
Suh, Kangho
You, Jaeeun
Lee, Je Ho
Joung, Kyung In
Suh, Dong Churl
International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility
title International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility
title_full International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility
title_fullStr International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility
title_full_unstemmed International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility
title_short International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility
title_sort international price comparisons of anticancer drugs: a scheme for improving patient accessibility
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830510/
https://www.ncbi.nlm.nih.gov/pubmed/33466893
http://dx.doi.org/10.3390/ijerph18020670
work_keys_str_mv AT jungjaeho internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility
AT kimdaejung internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility
AT suhkangho internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility
AT youjaeeun internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility
AT leejeho internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility
AT joungkyungin internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility
AT suhdongchurl internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility